New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:22 EDTTROVTrovagene to study transrenal BRAF mutations in primary and metastatic cancers
Trovagene announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. Researchers will use Trovagene's proprietary transrenal DNA, or TrDNA, detection technology to evaluate BRAF mutation status in urine as compared to tissue biopsy. The study also calls for monitoring of mutation levels in the urine at planned intervals during and after treatment to assess outcomes including: response rate; stable disease; progression-free survival; and overall survival. Results from patients who receive therapy that reflects their BRAF mutation status will be compared to outcomes for patients who receive standard-of-care therapy regardless of mutation status.
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
08:14 EDTTROVPeer-reviewed journal features Trovagene's cancer monitoring technology
Trovagene announced the publication of clinical study results in a peer-reviewed journal, Cancer Discovery, featuring the Company's precision cancer monitoring technology and its ability to non-invasively determine oncogene mutation status and monitor response to BRAF inhibitor therapy in patients with histiocytic disease, a malignancy often associated with BRAF mutations. Clinical results will be presented at the 30th Annual Histiocyte Society Meeting on October 28 in Toronto, Canada.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use